๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
UFP Technologies, Inc. (UFPT)
NASDAQ: UFPT ยท Real-Time Price ยท USD
298.93
-6.72 (-2.20%)
At close: Nov 19, 2026, 4:00 PM EST
304.00
+5.07 (1.70%)
After-hours: Nov 19, 2026, 5:02 PM EST

UFP Technologies Earnings Call Transcripts

Fiscal Year 2026

  • Q3 sales grew 11.6%, with 11.1% organic growth and higher gross margin; adjusted EPS was $2.88. Focus areas include scaling DAS Medical, completing delayed AJR transfers, and pursuing disciplined acquisitions into 2027.

  • A global CDMO in the medical device sector leverages early design involvement, high switching costs, and a scalable platform to drive organic and acquisitive growth. With a robust M&A pipeline and disciplined capital allocation, it targets double-digit revenue growth in a fragmented market.

  • Q2 2026 saw 15.1% sales growth, record adjusted EPS, and broad-based MedTech strength. Gross margin improved, backlog and labor issues were resolved, and investments in capacity and leadership support future growth. Organic growth is expected to normalize for the rest of the year.

  • A new CEO leads a seasoned team, maintaining a strategy focused on organic growth and targeted M&A in the medtech CDMO sector. The company targets 12โ€“18% annual revenue growth, prioritizes high-value segments like robotic surgery and patient beds, and leverages global operations and supplier partnerships for durable, diversified growth.

  • AGM 2026

    The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by majority vote. Final voting results will be published in a Form 8-K filing.

  • Revenue grew 4.1% year-over-year, led by strong medical segment growth and new program launches, while non-medical sales declined as automotive is phased out. Margin improvement is expected in the second half as new programs ramp and cost headwinds subside.

  • A leading CDMO in medical devices leverages exclusive material access, strategic acquisitions, and deep customer partnerships to drive high-margin growth. Recent contract extensions, robust financial performance, and expansion into new geographies position the company for continued outperformance.

Fiscal Year 2025

Fiscal Year 2024

  • The company is executing a two-pronged growth strategy, combining targeted internal expansion with strategic acquisitions, and has strengthened its position in med tech and infection prevention markets. Key partnerships, especially with Intuitive Surgical, and recent capacity expansions support continued margin improvement and growth.

  • The company leverages exclusive material partnerships and advanced engineering to serve leading medtech clients, focusing on high-margin, customer-funded development and international expansion. Recent acquisitions have enhanced capabilities, geographic reach, and operational efficiency, supporting strong financial targets and a robust growth outlook.

Fiscal Year 2021

Fiscal Year 2020